Data from the NERO study investigating Zejula in mesothelioma was presented at the American Association of Cancer Research ...

The Imfinzi regimen reduced risk of death by 25%, with overall survival at two years at 82% compared to 75% in the control ...

Biopharmaceutical company Cullinan Therapeutics is due to begin a trial of its drug candidate CLN-978 for treating Sjögren’s ...

The FDA approved AstraZeneca's Truqap in November 2023 for the treatment of advanced HR-positive breast cancer.

The World Health Organization estimates that 50% of vaccines are wasted globally each year due to cold chain issues.

Pacira BioSciences has revealed that PCRX-201 has demonstrated improvements in individuals with knee osteoarthritis in a ...

The US FDA has confirmed proteinuria as an acceptable primary endpoint in Dimerix ‘s Phase III ACTION3 trial of DMX-200 for ...

MSD has reported outcomes from a Phase III trial of Keytruda (pembrolizumab) for treating head and neck squamous cell ...

Pfizer has reported positive results from a Phase III trial of sasanlimab and Bacillus Calmette-Guérin (BCG) for treating ...

J&J submitted a New Drug Application to the FDA for TAR-200 in January 2025 following positive data from the SunRISe-1 trial.

Despite the failures, ALX Oncology remains hopeful about evorpacept and is focusing on combination trials with other ...

Sanofi will halt the development of its oral tumour necrosis factor (TNF) inhibitor balinatunfib as a monotherapy after it ...